22.692 articles found

Domestic violence and mistreatment in patients with parkinsonism: case reports, mechanisms, and discussion.

Nazir T, Thomson AM.

Mov Disord · 2010-12-13

DOI: 10.1002/mds.23438PMID: 21506158

Stem cells for the treatment of neurodegenerative diseases.

Dantuma E, Merchant S, Sugaya K.

Stem Cell Res Ther · 2010-12-10

DOI: 10.1186/scrt37PMID: 21144012

The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys.

Gilmour TP, Lieu CA, Nolt MJ, Piallat B, Deogaonkar M, Subramanian T.

Exp Neurol · 2010-12-10

DOI: 10.1016/j.expneurol.2010.12.001PMID: 21146527

A NEW ASYMMETRIC METHOD FOR THE SYNTHESIS OF RIVASTIGMINE HYDROGEN TARTRATE, CRYSTAL FORM TYPE II, ITS IMPLEMENTATION FOR PREPARING ORAL SOLUTION FOR THE TREATMENT OF DEMENTIA AND DEPENDENCES

FAMPIOS GEORGIOS SPYRIDONOS.

· 2010-12-09

Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field.

Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD.

Addiction · 2010-12-07

DOI: 10.1111/j.1360-0443.2010.03218.xPMID: 21134016

Potential sources of stem cells as a regenerative therapy for Parkinson's disease.

El-Sadik AO.

Stem Cells Cloning · 2010-12-06

DOI: 10.2147/sccaa.s14626PMID: 24198524

Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment.

Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR.

Eur J Neurol · 2010-12-01

DOI: 10.1111/j.1468-1331.2010.03063.xPMID: 20491889

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P, BIA-3202-202 Study Investigators.

CNS Neurosci Ther · 2010-12-01

DOI: 10.1111/j.1755-5949.2010.00145.xPMID: 20653695

Molecular chaperones as rational drug targets for Parkinson's disease therapeutics.

Kalia SK, Kalia LV, McLean PJ.

CNS Neurol Disord Drug Targets · 2010-12-01

DOI: 10.2174/187152710793237386PMID: 20942788

Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients.

Ricci V, Pomponi M, Martinotti G, Bentivoglio A, Loria G, Bernardini S, Caltagirone C, Bria P, Angelucci F.

J Clin Psychopharmacol · 2010-12-01

DOI: 10.1097/jcp.0b013e3181fc2ec7PMID: 21057246

Gene therapy for Parkinson's disease: do we have the cure?

Benabid AL.

Lancet Neurol · 2010-12-01

DOI: 10.1016/s1474-4422(10)70256-8PMID: 21087733

Gene therapy for Parkinson's disease: where are we now and where are we going?

Forsayeth J, Bankiewicz KS, Aminoff MJ.

Expert Rev Neurother · 2010-12-01

DOI: 10.1586/ern.10.161PMID: 21091315